Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

(MedPage Today) — The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday.
Approval stipulates use of the combination, with or without bevacizumab, in adults…

Source link : https://www.medpagetoday.com/hematologyoncology/ovariancancer/119831

Author :

Publish date : 2026-02-10 22:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

Gene Therapy Shows Signs of Delayed Progression in Fatal Neurodegenerative Disease

FDA Clears AI Program for Lung Cancer Screening

Related Posts

Dentists return £900m for not seeing NHS patients

These ER Docs Are Being Ousted After 35 Years. They’re Not Going Quietly.

Drug Cuts Albuminuria in Type 1 Diabetic Kidney Disease, Too

Drug breakthrough for children with severe form of epilepsy

Rapid RSV Tests Can Cut Down on Unneeded Antibiotics, Study Suggests

Study Identifies Factors Linked to Early Melanoma Recurrence

Dentists return £900m for not seeing NHS patients

These ER Docs Are Being Ousted After 35 Years. They’re Not Going Quietly.

Drug Cuts Albuminuria in Type 1 Diabetic Kidney Disease, Too

Drug breakthrough for children with severe form of epilepsy

Rapid RSV Tests Can Cut Down on Unneeded Antibiotics, Study Suggests

Study Identifies Factors Linked to Early Melanoma Recurrence

Parkinson’s Protein Linked to Faster Alzheimer’s Progression in Women

Prolonged Amoxicillin Challenge Checks Penicillin Allergy

Categories

Archives